Heska (HSKA) Completes Sale of Allergy Patent Portfolio
More News related to HSKA
- Heska Announces Q309 Results
- Webcast Alert: Heska Announces Third Quarter 2009 Earnings Conference Call Webcast
- Heska (HSKA) Reports Higher Q3 Earnings; Promotes McGinley to Positions of President and COO
- StreetInsider.com Unusual 11 Mid-Day Movers 05/08/2007
- Heska (HSKA) Completes Sale of Allergy Patent Portfolio
More News related to Mergers and Acquisitions
- Communications Systems (JCS) Reports Year-Over-Year Decline in Q3 Earnings
- Communications Systems (JCS) Posts Q3 EPS of $0.22, Down Y/Y
- Atmos Energy (ATO) Posts Q4 Loss of $0.17, Wider than Estimates
- China Digital TV (STV) Misses Q3 EPS by 2c; Guides Below for Q4
- Ralcorp (RAH) Misses Street's Q4 Views; Announces 7M Share Buyback
Heska Corporation (Nasdaq: HSKA) has completed the sale of its rights in a worldwide patent portfolio covering a number of major allergens and the genes that encode them to Allergopharma Joachim Ganzer KG for an undisclosed sum. As part of the agreement, Heska Corporation has exclusively licensed veterinary rights to the portfolio.
"This agreement provides us with additional capital as well as exclusive veterinary rights to the technology underlying this patent portfolio," said Robert Grieve, Heska's Chairman and CEO. "We intend to continue to focus our resources on the companion animal health market."
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
